~~<i id='D8248F5265'><strike id='D8248F5265'><tt id='D8248F5265'><pre id='D8248F5265'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-10-01 00:23:09 Page View：4612

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The aspartame in Diet Coke probably isn’t giving you cancer
Next article： Heart attack and stroke risk calculators need revising

focus

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Eisai exec who led development of Alzheimer’s drug to retire

IvanCheungisretiringaschairmanofEisai'sU.S.operationsandglobalheadofitsAlzheimer’sdiseaseunit.Chanta

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

As Maui death toll rises, number of missing remains unclear

3:12MembersoftheSearchandRecoveryTeam,accompaniedbycadaverdogs,checkareasdestroyedbywildfiresinLahai

WSS

explore

explore

comprehensive

focus

As Maui death toll rises, number of missing remains unclear